USE OF SULFAMETHOXAZOLE AND TRIMETHOPRIM IN IMMUNOSUPPRESSED PATIENTS FOR PNEUMONIA PROPHYLAXIS
PDF (Português (Brasil))

Keywords

sulfamethoxazole and trimethoprim; immunosuppressed; pneumonia

How to Cite

Carneiro, M. M., Freitas , P. H. de O. L. R., Barcelos , F. A., Cumani , M. C. B., & Mota, G. G. (2024). USE OF SULFAMETHOXAZOLE AND TRIMETHOPRIM IN IMMUNOSUPPRESSED PATIENTS FOR PNEUMONIA PROPHYLAXIS. Brazilian Journal of Implantology and Health Sciences, 6(8), 5826–5839. https://doi.org/10.36557/2674-8169.2024v6n8p5826-5839

Abstract

Introduction: Given the increased susceptibility to bacterial infections in immunosuppressed patients, the use of sulfamethoxazole and trimethoprim is justified by its relevance in reducing severe bacterial conditions, with pneumonia being a significant cause of morbidity and mortality in these individuals. Objective: To investigate, interpret, and review the findings on pneumonia in immunosuppressed patients, and the use of Sulfamethoxazole and Trimethoprim in the prophylaxis of this disease, evaluating the efficacy, safety, and monitoring of these patients with higher immunological vulnerability. Methodology: The Medical Literature Analysis and Retrieval System Online (MEDLINE/PubMed) database was used, with the descriptors sulfamethoxazole and trimethoprim; immunosuppressed; pneumonia, selecting review articles and original articles following eligibility criteria. A total of 695 texts were found, with an initial selection of 507, from which 39 eligible articles remained. Results: The articles, written in English, included publications from authors and journals of different nationalities. Final considerations: The use of SMX/TMP is a promising alternative for the prophylactic treatment of pneumonia in immunosuppressed patients, given the growing number of people undergoing immunosuppressive therapies for various medical conditions. However, the lack of studies on long-term safety, its role in the development of resistant variant bacteria, and the adverse effects caused by the drug highlight the need for further research on these drugs in this condition, to minimize the potential harms and achieve a more efficient therapeutic response.

https://doi.org/10.36557/2674-8169.2024v6n8p5826-5839
PDF (Português (Brasil))

References

BARAN, Karolina et al. Pneumocystis jirovecii Pneumonia in a Liver Transplant Recipient With an Adverse Reaction to Trimethoprim/Sulfamethoxazole Treated With a Sulfonamide Desensitization Protocol: Case Report. In: Transplantation Proceedings. Elsevier, 2024. p. 1000-1005.

GULHATI, Vishrut; DESY, Janeve; THORNTON, Christina S. A case of hypercalcemia from Pneumocystis jirovecii in an immunosuppressed non-HIV patient. BMC Pulmonary Medicine, v. 24, n. 1, p. 204, 2024.

MIYAKE, Kohei et al. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study. PloS one, v. 19, n. 2, p. e0292507, 2024.

MACHET, Thomas et al. Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: a French multicentre retrospective study in 116 patients. Joint Bone Spine, v. 90, n. 5, p. 105591, 2023.

HÄNSEL, L. et al. How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?. Clinical Microbiology and Infection, v. 29, n. 8, p. 1015-1023, 2023.

DACCO, Valeria et al. Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment. Pediatric Pulmonology, v. 58, n. 5, p. 1337-1343, 2023.

RUBIN, Limor et al. Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Frontiers in Immunology, v. 14, p. 1134178, 2023.

HUANG, Jingda et al. Case report: A HIV-negative hemodialysis patient positive for pANCA with severe pneumocystis pneumonia: A case report and review of literature. Medicine, v. 102, n. 12, p. e33351, 2023.

LI, Ziling et al. Pneumocystis pneumonia in a patient with diabetes mellitus: A case report. Medicine, v. 102, n. 5, p. e32290, 2023.

SIERRA, Caroline M.; DAIYA, Krishna C. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: a systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, v. 42, n. 11, p. 858-867, 2022.

TAKAHASHI, Tomoyuki et al. Pneumocystis jirovecii pneumonia associated with COVID-19 in patients with interstitial pneumonia. Medicina, v. 58, n. 9, p. 1151, 2022.

STAIR, Melissa I. et al. The Epidemiology of Invasive, Multipleantibiotic–resistant Klebsiella pneumoniae Infection in a Breeding Colony of Immunocompromised NSG Mice. Comparative Medicine, v. 72, n. 4, p. 220-229, 2022.

HAMID, Norbainun Che et al. Pneumocystis jirovecii Pneumonia with a Normal Early Chest Radiography and Complicated with Drug-Induced Immune Hemolytic Anemia: A Case Report. The American Journal of Case Reports, v. 23, p. e936278-1, 2022.

BOROJEVIC, Branko et al. Pneumocystis pneumonia with respiratory failure in a HIV-negative patient following short course of low-dose to moderate-dose prednisolone for a dermatological condition. BMJ Case Reports CP, v. 15, n. 6, p. e249346, 2022.

OMORI, Koji et al. Acute exacerbation of pulmonary toxoplasmosis during corticosteroid therapy for immune thrombocytopenia: A case report and literature review. Medicine, v. 100, n. 51, p. e28430, 2021.

LEW, Jeffrey et al. Increased Rates of rhabdomyolysis in male hematopoietic cell transplantation recipients taking sirolimus and trimethoprim/sulfamethoxazole. Transplantation and cellular therapy, v. 27, n. 12, p. 1019. e1-1019. e4, 2021.

CHONG, Woon H.; SAHA, Biplab K.; CHOPRA, Amit. Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?. Infection, v. 49, n. 6, p. 1079-1090, 2021.

PUING, Alfredo G. et al. Nocardiosis in immunocompromised patients on alternative pneumocystis prophylaxis. Emerging Infectious Diseases, v. 27, n. 10, p. 2734, 2021.

ARAKAWA, Naoki et al. Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient. Internal Medicine, v. 60, n. 19, p. 3143-3147, 2021.

PROUDFOOT, Rebecca Hilary; PHILLIPS, Bob. UK paediatric oncology Pneumocystis jirovecii pneumonia surveillance study. Archives of Disease in Childhood, v. 106, n. 10, p. 994-998, 2021.

ABE, Seitaro et al. Case report: pulmonary nocardiosis caused by Nocardia exalbida in an immunocompetent patient. BMC Infectious Diseases, v. 21, p. 1-6, 2021.

YU, Qian et al. Pneumocystis jiroveci pneumonia with cytomegalovirus infection diagnosed by metagenomic next-generation sequencing in a patient with nephrotic syndrome: A case report. Medicine, v. 100, n. 31, p. e26842, 2021.

PAZ, David Luque et al. Pneumocystis in metastatic lung cancer, a pragmatic approach in support of prophylaxis. BMJ Case Reports CP, v. 14, n. 6, p. e232895, 2021.

YUNO, Akiko et al. Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. Endocrine Journal, v. 68, n. 4, p. 477-484, 2021.

SCHWENK, Hayden T. et al. Toxoplasmosis in pediatric hematopoietic stem cell transplantation patients. Transplantation and Cellular Therapy, v. 27, n. 4, p. 292-300, 2021.

MAALIKI, Naji et al. Unusual aetiology of respiratory compromise in a patient with AIDS. BMJ Case Reports CP, v. 14, n. 3, p. e240849, 2021.

MIESEL, Lynn et al. Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and pneumocystis pneumonia. Antimicrobial Agents and Chemotherapy, v. 65, n. 3, p. 10.1128/aac. 01992-20, 2021.

QUINTANA-ORTEGA, Cristian et al. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Modern rheumatology case reports, v. 5, n. 1, p. 101-107, 2021.

REDDY, Y. Muralidhar et al. Nocardiosis—an uncommon infection in patients with myasthenia gravis: report of three cases and review of literature. BMJ Case Reports CP, v. 13, n. 12, p. e237208, 2020.

ANDREI, Stefan et al. Successful treatment of pulmonary haemorrhage and acute respiratory distress syndrome caused by fulminant Stenotrophomonas maltophilia respiratory infection in a patient with acute lymphoblastic leukaemia–case report. BMC Infectious Diseases, v. 20, p. 1-6, 2020.

CHEN, Yan-Hui et al. Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China. Brazilian Journal of Microbiology, v. 51, p. 1061-1069, 2020.

MOHAMED, Mohamed A. et al. Renal transplant recipient with concurrent COVID-19 and Stenotrophomonas maltophilia pneumonia treated with trimethoprim/sulfamethoxazole leading to acute kidney injury: a therapeutic dilemma. The American journal of case reports, v. 21, p. e926464-1, 2020.

LI, Cong et al. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy. BMC cancer, v. 20, p. 1-7, 2020.

DELBOVE, Agathe et al. Pneumocystis pneumonia after lung transplantation: a retrospective multicenter study. Respiratory Medicine, v. 169, p. 106019, 2020.

KOJIMA, Kentaro et al. Clinical characteristics and risk factors for pneumocystis jirovecii pneumonia during immunosuppressive treatment in patients with ulcerative colitis: a retrospective study. Journal of Gastrointestinal & Liver Diseases, v. 29, n. 2, 2020.

GUILLAUME, Zoé et al. Severe cellular immunodeficiency triggered by the CDK4/6 inhibitor palbociclib. Clinical Breast Cancer, v. 20, n. 2, p. e192-e195, 2020.

WANG, Lili et al. Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017. Medicine, v. 99, n. 8, p. e19250, 2020.

IMOTO, Waki et al. Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Internal Medicine, v. 59, n. 2, p. 193-198, 2020.

MURAMATSU, Hirotada et al. A co-infection of varicella-zoster virus and Pneumocystis jirovecii in a non-HIV immunocompromised patient: a case report. BMC Infectious Diseases, v. 19, p. 1-4, 2019.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Mylena Moraes Carneiro, Pedro Henrique de Oliveira Langoni Ribeiro Freitas , Fernando Afonso Barcelos , Maria Cecília Brant Cumani , Gabriela Gobbi Mota

Downloads

Download data is not yet available.